Skip to content

Comparison of two drugs, empagliflozin and dapagliflozin, in the development of urinary tract infections in women with high blood sugar

Comparison of empagliflozin and dapagliflozin in the incidence of urinary tract infection in women with diabetes

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250129064554N1
Enrollment
84
Registered
2025-04-15
Start date
2024-10-11
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary tract infection.

Interventions

Intervention 1: Intervention group:Empagliflozin. Intervention 2: Intervention group:Dapagliflozin.

Sponsors

Artesh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Women with diabetes (type 1 or 2) Women over 18 years of age No physical or psychological barriers to active participation in the study. Consent to participate in the study and take the study medication.

Exclusion criteria

Exclusion criteria: Intolerance or adverse reaction to the study drugs. Having serious side effects from the drugs. Being pregnant

Design outcomes

Primary

MeasureTime frame
Percentage of people who get urinary tract infections. Timepoint: Three months after taking the drug?. Method of measurement: Urinalysis and urine culture test.

Secondary

MeasureTime frame
Percentage of people who experience drug side effects. Timepoint: Three months after taking the medication. Method of measurement: Urinalysis and urine culture.;Percentage of people whose blood sugar is controlled with the study drugs. Timepoint: Three months after taking the medication. Method of measurement: Urinalysis and urine culture.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSarah Keshkari

Artesh University of Medical Sciences

Skeshtkari1@gmail.com+98 21 8609 6350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026